Condition

HR-positive, HER2-negative Advanced Breast Cancer

ClinicalTrials.gov condition label

Clinical trials4

Recruiting3

Common interventions11

Lead sponsors shown4

Clinical trials

4 shown

Open-Label Study of BBO-10203 in Subjects With Advanced Solid TumorsNCT06625775 · 2024-10-29

Study of TYK-00540 Tablets in Patients With Advanced Solid TumorsNCT06950086 · 2024-01-02

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 StudyNCT06805812 · 2023-05-01

A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast CancerNCT04796623 · 2021-02-04

Common interventions

RibociclibDRUG2 AbemaciclibDRUG1 BBO-10203DRUG1 BevacizumabDRUG1 FOLFOXDRUG1 FulvestrantDRUG1 Fulvestrant injectionDRUG1 PalbociclibDRUG1 TQB3616 capsulesDRUG1 TrastuzumabDRUG1 TYK-00540DRUG1

Leading sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.1 Fondazione IRCCS Istituto Nazionale dei Tumori, Milano1 TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)1 TYK Medicines, Inc1

Trial status mix

RECRUITING3

COMPLETED1

Phase mix

PHASE12

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.